The localization of oxytocin (OT) binding sites and vasopressin (VP) binding sites of the V1a subtype was investigated by radioautography in kidneys of rabbits, mice and meriones during postnatal development and in the adult, and in the human kidney. Kidney sections were incubated in the presence of selective radioiodinated OT and V1a antagonists, respectively. The localizations were compared with those previously described in the rat. The main finding of the study was the almost constant presence in the cortex of V1a binding sites in the connecting tubule, the cortical collecting duct and in the juxtaglomerular apparatus (on the intra- and extraglomerular mesangium and the afferent arteriole). This distribution suggests an interaction of VP via V1a receptors and the kallikrein-kinin system in the kidney. OT binding sites, in comparison with V1a binding sites, were fewer and less constantly detectable in the kidney of the different species. In the mouse, their presence on the limbs of Henle’s loop in the medulla points to the possibility of their involvement in the medullary concentrating process. In the kidneys of the various species, OT and V1a binding sites occurred always in differential structures. In contrast, in the human kidney cortex, a colocalization of OT and V1a binding sites was almost constantly observed. This raises the question as to the specificity of the neurohypophysial hormone receptors in the human kidney.

Keywords:
Historadioautography, V1a receptors, OT receptors, Rodents, Human, Nephron, Renal vessels
1.
Handler JS, Orloff J: Antidiuretic hormone. Annu Rev Physiol 1981;43:611–624.
2.
Morel F, Imbert-Teboul M, Chabardès D: Receptors to vasopressin and other hormones in the mammalian kidney. Kidney Int 1987;31:512–520.
3.
Wittner M, Di Stefano A, Wangemann P, Nitschke R, Greger R, Bailly C, Amiel C, Roinel N, De Rouffignac C: Differential effects of magnesium transport in cortical and medullary thick ascending limbs of mouse nephron. Pflügers Arch 1988;412:516–523.
4.
Arpin-Bott MP, Waltisperger E, Freund-Mercier MJ, Stoeckel ME: Two oxytocin-binding sites subtypes in rat kidney: Pharmacological characterization, ontogeny and localization by in vitro and in vivo autoradiography. J Endocrinol 1997;153:49–59.
5.
Arpin-Bott MP, Waltisperger E, Freund-Mercier MJ, Stoeckel ME: Historadioautographic localization, pharmacology and ontogeny of V1a vasopressin binding sites in the rat kidney. Nephron 1999;83:74–84.
6.
Jamison RL, Kriz W: Urinary Concentrating Mechanism: Structure and Function. New York, Oxford University Press, 1982.
7.
Bankir L, De Rouffignac C: Urinary concentrating ability: Insights from comparative anatomy. Am J Physiol 1985;249:R643–R666.
8.
Kriz W, Koepsell H: The structural organization of the mouse kidney. Z Anat Entwickl Gesch 1974;144:37–163.
9.
Kaissling B, Kriz W: Sructural analysis of the rabbit kidney. Adv Anat Embryol Cell Biol 1979;56:1–123.
10.
Kaissling B, Kriz W: Structural organization of the mammalian kidney; in Seldin DW, Giebisch G (eds): The Kidney: Physiology and Pathophysiology. New York, Raven Press, 1985, pp 265–306.
11.
Kriz W, Bankir L: A standard nomenclature for structures of kidney. Am J Physiol 1988;254:F1–F8.
12.
Kriz W: Structural organization of the renal medulla: Comparative and functional aspects. Am J Physiol 1981;241:R3–R16.
13.
Kriz W, Schermann J, Koepsell H: The position of short and long loops of Henle in the rat kidney. Z Anat Entwickl Gesch 1972;138:301–319.
14.
Burnatowska-Hledin MA, Spielman WS: Vasopressin V1 receptors on the principal cells of the rabbit cortical collecting tubule. J Clin Invest 1989;83:84–89.
15.
Ando Y, Tabei K, Asano Y: Luminal vasopressin modulates transport in the rabbit cortical collecting duct. J Clin Invest 1991;88:952–959.
16.
Ando Y, Asano Y: Functional evidence for an apical V1 receptor in rabbit cortical collecting duct. Am J Physiol 1993;264:467–471.
17.
Yoshitomi K, Naruse M, Hanaoka K, Yamamura Y, Imai M, Kurokawa K: Functional characterization of vasopressin V1 and V2 receptors in the rabbit renal cortical collecting duct. Kidney Int 1996;49 (suppl 55): S177–S182.
18.
Jaisser F, Bugeon L, Blot-Chabot M, Bonvalet JP, Farman N: Effects of AVP and dDAVP on PGE2 synthesis in surperfused collecting ducts. Am J Physiol 1989;256:F1044–F1050.
19.
Naruse M, Inoue T, Nakayama M, Kurokawa K, Sato T: Oxytocin affects apical sodium conductance in rabbit cortical collecting duct cells; in Gross P, Richter D, Robertson GL (eds): Vasopressin. London, John Libbey Eurotext, 1993, pp 289–299.
20.
Edwards RM, Trizna W, Kinter LB: Renal microvascular effects of vasopressin and vasopressin antagonists. Am J Physiol 1989;256:F274.
21.
Garg LC, Kapturczak E: Stimulation of phosphoinositide hydrolysis in renal medulla by vasopressin. Endocrinology 1990;127:1022–1027.
22.
Burnatowska-Hledin MA, Spielman WS, Smith WL, Shi P, Meyer JM, Dewitt DL: Expression cloning of an AVP-activated, calcium mobilizing receptor from rabbit kidney medulla. Am J Physiol 1995;268:1198–1210.
23.
Naruse M, Uchida S, Ogata E, Kurokawa K: Endothelin 1 increases cell calcium in mouse collecting tubule cells. Am J Physiol 1991;161:720–725.
24.
Gonzalez CB, Figueroa CD, Reyes CE, Caorsi CE, Troncoso S, Menzel D: Immunolocalization of V1 vasopressin receptors in rat kidney using anti-receptor antibodies. Kidney Int 1997;52:1206–1215.
25.
Kostoglou-Athanassiou I, Treacher DF, Forsling ML: Is oxytocin natriuretic in man? (abstract). J Endocr 1994;143:39.
26.
Stoeckel ME, Freund-Mercier MJ: Autoradiographic demonstration of oxytocin binding sites in the macula densa. Am J Physiol 1989;257:F310–F314.
27.
Herkenham M, Pert CB: Light microscopic localization of brain opiate receptors: A general autoradiographic method which preserves tissue quality. J Neuroscience 1982;2:1129–1149.
28.
Audigier S, Barberis C: Pharmacological characterization of two specific binding sites for neurohypophyseal hormones in hippocampal synaptic plasma membranes of the rat. EMBO J 1985;4:1407–1412.
29.
Barberis C, Tribollet E: Vasopressin and oxytocin receptors in the central nervous system. Crit Rev Neurobiol 1996;10:119–154.
30.
Manning ML, Cheng L, Stoev S, Sawyer WH, Tribollet E, Barberis C, Wo NC, Chan WY: Novel potent and selective antagonists and radioiodinated ligands for oxytocin and vasopressin receptors; in Saito T, Kurokawa K, Yoshida S (eds): Neurohypophysis: Recent Progress of Vasopressin and Oxytocin Research. New York, Elsevier Science, 1995, pp 21–38.
31.
Thibonnier M, Conarty DM, Preston JA, Wilkins PL, Berti-Mattera LN, Mattera R: Molecular pharmacology of human vasopressin receptors; in Zingg et al. (eds): Vasopressin and Oxytocin. New York, Plenum Press, 1998.
32.
Schmidt A, Audigier S, Barberis C, Jard S, Manning M, Kolodziejczyk AS, Sawyer WH: A radioiodinated linear vasopressin antagonist: A ligand with high affinity and specificity for V1a receptors. FEBS Lett 1991;282:77–81.
33.
Rozen F, Russo C, Banville D, Zingg HH: Structure, characterization and expression of the rat oxytocin receptor gene. Proc Natl Acad Sci USA 1995;92:200–204.
34.
Kimura T, Tanizana O, Mori K, Brownstein MJ, Okayama H: Structure and expression of a human oxytocin receptor. Nature 1992;356:526–529.
35.
Morel A, O’Caroll AM, Brownstein MJ, Lolait SJ: Molecular cloning and expression of a rat V1a arginine vasopressin receptor. Nature 1992;356:523–526.
36.
Thibonnier M, Auzan C, Madhun Z, Wilkins P, Berti-Mattera L, Clauser E: Molecular cloning, sequencing, and functional expression of a cDNA encoding the human V1a vasopressin receptor. J Biol Chem 1994;269:3304–3310.
37.
Sugimoto T, Saito M, Mochizuki S, Watanabe Y, Hashimoto S, Kawashima H: Molecular cloning and functional expression of a cDNA encoding the human V1b vasopressin receptor. J Biol Chem 1994;269:27088–27092.
38.
Lolait SJ, O’Carroll AM, McBride OW, Konig M, Morel A, Brownstein MJ: Cloning and characterization of a vasopressin V2 receptor and possible link to nephrogenic diabetes insipidus. Nature 1992;357:336–339.
39.
Pettibone DJ, Kishel MT, Woyden CJ, Clineschmidt BV, Bock MG, Freidinger RM, Veber DF, Williams PD: Radioligand binding studies reveal marked species differences in the vasopressin V1 receptor of rat, rhesus and human tissues. Life Sci 1992;50:1953–1958.
40.
Nakanishi K, Mattson DL, Grosse V, Roman RJ, Cowley AW: Control of renal medullary blood flow by vasopressin V1 and V2 receptors. Am J Physiol 1995;269:R193–R200.
41.
Fejes-Toth G, Zahajzky T, Filep J: Effects of vasopressin on renal kallikrein excretion. Am J Physiol 1980;239:F388–F392.
42.
Figueroa CD, Caorsi I, Subiabre J, Vio CP: Immunoreactive kallikrein localization in the rat kidney. J Histochem Cytochem 1984;32:117–126.
43.
Vio CP, Figueroa CD, Caorsi I: Localization of renal kallikrein in human kidney and its relationship with the juxtaglomerular apparatus. Am J Hypertens 1987;1:269–271.
44.
Schuster VL, Kokko JP, Jacobson HR: Interaction of lysil-bradykinin and antidiuretic hormone in the rabbit cortical collecting tubule. J Clin Invest 1984;73:1659–1667.
45.
Carvounis CP, Carvounis G, Arbeit LA: Role of the endogenous kallikrein-kinin system in modulating vasopressin-stimulated water flow and urea permeability in the toad urinary bladder. J Clin Invest 1981;67:1792–1796.
46.
Adachi K, Majima M, Katori M, Nihijima M: Oxytocin-induced natriuresis mediated by the renal kallikrein-kinin system in anaesthetized male rats. Jpn J Pharmacol 1995;67:243–252.
47.
Margolius HS: Kallikreins and kinins: Some unanswered questions about system characteristics and roles in human disease. Hypertension 1995;26:221–229.
48.
Majma M, Katori M: Approaches to the development of novel antihypertensive drugs: Crucial role of the renal kallikrein-kinin system. Trends Pharmacol Sci 1995;16:239–246.
49.
Trinh-Trang-Tan MM, Bankir L: Integrated function of urea transporters in the mammalian kidney. Exp Nephrol 1998;6:471–479.
© 2002 S. Karger AG, Basel
2002
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.